Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Low Dose GM-CSF, As Consolidation Treatment in Patients With Hematologic Malignancies

Trial Profile

Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Low Dose GM-CSF, As Consolidation Treatment in Patients With Hematologic Malignancies

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs KiroVAX 001 (Primary) ; Cyclophosphamide; Granulocyte macrophage colony stimulating factor
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Sponsors Kiromic
  • Most Recent Events

    • 01 Aug 2017 Planned End Date changed from 1 Sep 2017 to 31 Jan 2019.
    • 01 Aug 2017 Planned primary completion date changed from 1 May 2017 to 31 Oct 2018.
    • 01 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top